Solid Bioscience Stock Price, News & Analysis

Solid Biosciences (Nasdaq: SLDB) announced on January 5, 2026 an inducement grant of 7,000 restricted stock units (RSUs) to a newly hired employee under the company’s 2024 Inducement Stock Incentive Plan. The RSUs vest in four equal annual installments on each one-year anniversary of the grant date through the fourth anniversary, subject to the employee’s continued service.

The grant was made as an inducement material to the employee’s acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (Nasdaq: SLDB) announced that Duchenne muscular dystrophy was added to the U.S. Recommended Uniform Screening Panel (RUSP) on Dec. 16, 2025, making it recommended for universal newborn screening.

Solid noted its long-term advocacy role, including participation on PPMD’s steering committee and a New York state pilot completed in 2021. The company said RUSP inclusion is expected to accelerate detection and enable earlier access to specialists, supportive interventions, and treatments.

Solid reiterated its focus on advancing its investigational gene therapy SGT-003 for Duchenne while celebrating earlier diagnosis and resource access for families.

Solid Biosciences (Nasdaq: SLDB) will present new data on its next-generation capsid AAV-SLB101 and cardiac gene therapy pipeline at the 22nd Global CardioVascular Clinical Trialists Forum, December 8-10, 2025, in Washington, D.C.

Chief Medical Officer Gabriel Brooks, M.D. will present two talks, a poster on AAV-SLB101 showing potent cardiac tropism and initial clinical safety, and join two panels; Nicolas Christoforou, Ph.D. will present preclinical work on a gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT) and join a panel.

Presentations will be posted after the conference on the company’s Scientific Publications & Presentations page.

Solid Biosciences (Nasdaq: SLDB) announced on December 1, 2025 that it granted a total of 23,284 restricted stock units (RSUs) to two newly hired employees as inducement awards under the company’s 2024 Inducement Stock Incentive Plan.

The RSUs vest in four equal installments on each one-year anniversary of the grant date through the fourth anniversary, and vesting is subject to the employees' continued service. The awards were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences (Nasdaq: SLDB) announced on Dec 1, 2025 that the FDA granted Rare Pediatric Disease designation to SGT-212, its investigational dual-route gene therapy for Friedreich’s ataxia (FA).

SGT-212 delivers the full-length frataxin gene via both intradentate nucleus (IDN) and intravenous (IV) administration and has previously received Fast Track designation. The Rare Pediatric Disease designation makes SGT-212 potentially eligible for a pediatric priority review voucher (PRV), which can expedite future biologics review or be sold or transferred. The company said screening is underway for the FALCON Phase 1b first-in-human trial.

Solid Biosciences (Nasdaq: SLDB) announced a non-exclusive worldwide license and collaboration with Andelyn Biosciences for Solid’s proprietary next-generation capsid AAV-SLB101 on Nov 17, 2025. The agreement lets Andelyn offer AAV-SLB101 to gene therapy clients via its AAV Curator® Platform; financial terms were not disclosed. AAV-SLB101 has shown robust preclinical cardiac and skeletal muscle transduction and, as of the safety cutoff on Oct 31, 2025, was generally well tolerated in 23 pediatric participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial (NCT06138639). Solid reports >30 existing agreements/licenses for AAV-SLB101, and the deal aims to broaden access to the capsid for early-stage programs.

Solid Biosciences (Nasdaq: SLDB) will participate in two investor conferences in late 2025 with senior management presenting in fireside chats.

• Jefferies Global Healthcare Conference (London) — Bo Cumbo, President and CEO, and Gabriel Brooks, MD, Chief Medical Officer, will speak on Nov 18, 2025 at 11:00 a.m. GMT (6:00 a.m. ET).
• Piper Sandler 37th Annual Healthcare Conference — the same executives will speak on Dec 2, 2025 at 11:30 a.m. ET.

Live webcasts will be available on the company Investors Events page, and replay files will be archived there for 30 days. Institutional investors seeking one-on-one meetings should contact their Jefferies or Piper Sandler representatives.

Solid Biosciences (NASDAQ: SLDB) announced that SGT-003, its investigational gene therapy for Duchenne muscular dystrophy, was granted an Innovation Passport under the UK Innovative Licensing and Access Pathway (ILAP) on November 6, 2025. The Passport activates MHRA and ILAP partner agencies to develop a product-specific roadmap intended to accelerate regulatory timelines and patient access in the UK.

SGT-003 is one of the first three products in the new ILAP. Clinical development continues: the Phase 1/2 INSPIRE DUCHENNE trial is enrolling across 15 sites in the US, UK, Italy and Canada, and Solid has activated the first site and begun screening for the ex-US Phase 3 IMPACT DUCHENNE trial.

Solid Biosciences (Nasdaq: SLDB) announced on Nov. 4, 2025 that it granted a total of 26,550 restricted stock units (RSUs) to two newly hired employees as inducements under its 2024 Inducement Stock Incentive Plan.

The RSUs vest in four equal annual installments on each one‑year anniversary of the grant date through the fourth anniversary, and vesting is subject to each employee's continued service. The grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).